Rhenman & Partners Asset Management AB Decreases Stake in Al

Rhenman & Partners Asset Management AB decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 7,500 […]

Related Keywords

Wellington , New Zealand General , New Zealand , London , City Of , United Kingdom , William Blair , Amyw Schulman , Wellington Management Group , News Ratings For Alnylam Pharmaceuticals Daily , Quarter For Alnylam Pharmaceuticals , Royal London Asset Management Ltd , Cantor Fitzgerald , Alnylam Pharmaceuticals Inc , Hermes Inc , Securities Exchange Commission , Alnylam Pharmaceuticals Price Performance , Alnylam Pharmaceuticals , Norges Bank , Nasdaq , Goldman Sachs Group , Partners Asset Management , Free Report , Management Group , London Asset Management , Federated Hermes , Get Free Report , Director Amy , Visit Holdingschannel , Alnylam Pharmaceuticals Daily ,